Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trellus Health PLC ( (GB:TRLS) ) has shared an update.
Trellus Health PLC has signed a 12-month contract with a leading global clinical research organization to utilize its Trellus TrialSet™ offering, focusing on immunology and inflammation. This marks the company’s second contract with a major CRO, reinforcing its strategic growth in the clinical trials sector. The contract includes upfront, monthly, and milestone payments, and is structured around key performance indicators to optimize trial recruitment and reduce screen failure rates. This development highlights Trellus Health’s growing recognition in the pharmaceutical sector, although it does not immediately extend the company’s cash runway beyond December 2025.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that provides value-based innovative solutions and services aimed at helping individuals with chronic conditions manage their health. The company offers Trellus Elevate®, a digital platform that integrates data analytics with personalized resilience programs, focusing initially on chronic gastrointestinal conditions like Inflammatory Bowel Disease (IBD). Trellus Health also provides Trellus TrialSet™, a solution designed to enhance clinical trial recruitment and support pharmaceutical partners from trials to commercialization.
Average Trading Volume: 1,308,040
Technical Sentiment Signal: Sell
Current Market Cap: £888.3K
Learn more about TRLS stock on TipRanks’ Stock Analysis page.